Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Active not recruiting 3Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Colorectal Neoplasms 14Stomach Neoplasms 4Esophageal Squamous Cell Carcinoma 4Colonic Neoplasms 4Rectal Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasm Metastasis 3Esophageal Neoplasms 3Neoplasms 2Leukemia, Biphenotypic, Acute 2Intestinal Neoplasms 2Gastrointestinal Neoplasms 2Gastrointestinal Diseases 2Digestive System Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Adenocarcinoma Of Esophagus 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Diseases 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Mesothelioma, Malignant 1Melanoma 1Malignant Solid Tumour 1Lymphoma, Non-Hodgkin 1Intestinal Diseases 1Endometrial Neoplasms 1Digestive System Diseases 1

Interventions

Cisplatin 116Radiotherapy 84Paclitaxel 77Fluorouracil 62Carboplatin 41Drug Therapy 38pembrolizumab 33Irinotecan 33tislelizumab 27Docetaxel 26Neoadjuvant Therapy 24Oxaliplatin 23toripalimab 22sintilimab 19camrelizumab 19Radiation 19Esophagectomy 18Capecitabine 17130-nm albumin-bound paclitaxel 17Surgical Procedures, Operative 16Nivolumab 16Leucovorin 15Cetuximab 14TP protocol 12S 1 (combination) 12Radiotherapy, Intensity-Modulated 12Albumin-Bound Paclitaxel 12nimotuzumab 11apatinib 10Immune Checkpoint Inhibitors 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × Levoleucovorin × Clear all
NCT04210115 2026-05-13

KEYNOTE 975

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
703 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT05945823 2026-04-09

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Taiho Oncology, Inc.

Phase 2 Active not recruiting
53 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

NCT06780111 2026-03-31

MK-3475-06E

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
298 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04949256 2025-12-15

MK-7902-014

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
864 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡